Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival

International Journal of Cancer

Volumn 136, Issue 1, 2015, Pages 127-137

  De Remigis, Alessandra ^a   De Gruijl, Tanja D ^b   Uram, Jennifer N ^c   Tzou, Schey Cherng ^a   Iwama, Shintaro ^a   Talor, Monica V ^a   Armstrong, Todd D ^c   Santegoets, Saskia J A M ^b   Slovin, Susan F ^d,e   Zheng, Lei ^c   Laheru, Daniel A ^c   Jaffee, Elizabeth M ^c   Gerritsen, Winald R ^b   Van Den Eertwegh, Alfons J M ^b   Le, Dung T ^c   Caturegli, Patrizio ^a,f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

CTLA 4; GVAX; immunotherapy; thyroglobulin antibodies

Indexed keywords

ACTIN ANTIBODY; ANTIBODY; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INSULIN ANTIBODY; IPILIMUMAB; MYELOPEROXIDASE ANTIBODY; PROTEINASE 3 ANTIBODY; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AUTOANTIBODY; CANCER ANTIBODY; CANCER VACCINE; GVAX VACCINE; MESSENGER RNA; MONOCLONAL ANTIBODY; THYROGLOBULIN; THYROTROPIN;

ANTIBODY TITER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HASHIMOTO DISEASE; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; COLONIC NEOPLASMS; GENETICS; IMMUNOLOGY; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; SURVIVAL; TUMOR CELL LINE; VACCINATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COHORT STUDIES; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; MALE; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; RNA, MESSENGER; SURVIVAL ANALYSIS; THYROGLOBULIN; THYROTROPIN; VACCINATION;

EID: 84925286791     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28973     Document Type: Article

References (42)

1. Cha E, Fong L,. Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol 2011; 29: 3677-85.
2. Dranoff G, Jaffee E, Lazenby A, et al., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90:, 3539,-43.
3. Callahan MK, Wolchok JD,. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013; 94: 41-53.
4. van den Eertwegh AJ, Versluis J, van den Berg HP, et al., Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 509-17.
5. Le DT, Lutz, E, Uram, JN, et al., Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013; 36: 382-9.
6. Weber JS, Kahler KC, Hauschild A,. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-7.
7. Corsello SM, Barnabei A, Marchetti P, et al., Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013; 98: 1361-75.
8. Torino F, Barnabei A, Paragliola R, Baldelli R, Appetecchia M, Corsello SM,. Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid: official journal of the American Thyroid Association 2013; 23: 1345-66.
9. Weber J, Thompson JA, Hamid O, et al., A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15: 5591-8.
10. Downey SG, Klapper JA, Smith FO, et al., Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13: 6681-8.
11. Lutz E, Yeo CJ, Lillemoe KD, et al., A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011; 253: 328-35.
12. Yuan J, Ginsberg B, Page D, et al., CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother 2011; 60: 1137-46.
13. Yuan J, Adamow M, Ginsberg BA, et al., Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 2011; 108: 16723-8.
14. McGrogan A, Seaman HE, Wright JW, et al., The incidence of autoimmune thyroid disease: a systematic review of the literature. Clin Endocrinol 2008; 69: 687-96.
15. Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM,. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2013; 24: 1813-21.
16. Kimura H, Kimura M, Tzou SC, et al., Expression of class II major histocompatibility complex molecules on thyrocytes does not cause spontaneous thyroiditis but mildly increases its severity after immunization. Endocrinology 2005; 146: 1154-62.
17. Jaffee EM, Schutte M, Gossett J, et al., Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 1998; 4: 194-203.
18. Santegoets SJ, Stam AG, Lougheed SM, et al., T cell profiling reveals high CD4+CTLA-4-‰+-‰T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother 2013; 62: 245-56.
19. Simmons AD, Li B, Gonzalez-Edick M, Lin C, Moskalenko M, Du T, Creson J, VanRoey MJ, Jooss K,. GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer immunology, immunotherapy: CII 2007; 56: 1653-65.
20. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T,. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. The Journal of experimental medicine 1993; 178: 489-95.
21. Ahmad R, Raina D, Joshi MD, Kawano T, Ren J, Kharbanda S, Kufe D,. MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer research 2009; 69: 7013-21.
22. Chen YT, Gure AO, Tsang S, Stockert E, Jager E, Knuth A, Old LJ,. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 6919-23.
23. Seedorf K, Oltersdorf T, Krammer G, Rowekamp W,. Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. The EMBO journal 1987; 6: 139-44.
24. Stam K, Heisterkamp N, Grosveld G, de Klein A, Verma RS, Coleman M, Dosik H, Groffen J,. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. The New England journal of medicine 1985; 313: 1429-33.
25. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
26. Vita R, Guarneri F, Agah R, Benvenga S,. Autoimmune thyroid disease elicited by NY-ESO-1 vaccination. Thyroid: official journal of the American Thyroid Association 2014; 24: 390-4.
27. Hoekman K, von Blomberg-van der Flier BM, Wagstaff J, et al., Reversible thyroid dysfunction during treatment with GM-CSF. Lancet 1991; 338: 541-2.
28. Hansen PB, Johnsen HE, Hippe E,. Autoimmune hypothyroidism and granulocyte-macrophage colony-stimulating factor. Eur J Haematol 1993; 50: 183-4.
29. Di Giacomo A,. The EFIS-EJI Ruggero Ceppellini Advanced School of Immunology Innate Immunity 2012: from evolution to revolution. Eur J Immunol 2013; 43: 13-4.
30. Jaffee EM, Hruban RH, Biedrzycki B, et al., Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001; 19: 145-56.
31. Weijl NI, Van der Harst D, Brand A, et al., Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993; 11: 1376-83.
32. Schwartzentruber DJ, White DE, Zweig MH, et al., Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer 1991; 68: 2384-90.
33. Caturegli P, Mariotti S, Kuppers RC, et al., Epitopes on thyroglobulin: a study of patients with thyroid disease. Autoimmunity 1994; 18: 41-9.
34. Latrofa F, Ricci D, Grasso L, et al., Characterization of thyroglobulin epitopes in patients with autoimmune and non-autoimmune thyroid diseases using recombinant human monoclonal thyroglobulin autoantibodies. J Clin Endocrinol Metab 2008; 93: 591-6.
35. Krahn J, Dembinski T,. Thyroglobulin and anti-thyroglobulin assays in thyroid cancer monitoring. Clin Biochem 2009; 42: 416-19.
36. Latrofa F, Ricci D, Montanelli L, et al., Thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: comparison of different assays and evaluation of causes of discrepancies. J Clin Endocrinol Metab 2012; 97: 3974-82.
37. Taylor KP, Parkington D, Bradbury S, et al., Concordance between thyroglobulin antibody assays. Ann Clin Biochem 2011; 48: 367-9.
38. Tozzoli R, Bizzaro N, Tonutti E, et al., Immunoassay of anti-thyroid autoantibodies: high analytical variability in second generation methods. Clin Chem Lab Med 2002; 40: 568-73.
39. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA,. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2001; 19: 3477-82.
40. Franzke A, Peest D, Probst-Kepper M, Buer J, Kirchner GI, Brabant G, Kirchner H, Ganser A, Atzpodien J,. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 1999; 17: 529-33.
41. Luiten RM, Kueter EW, Mooi W, et al., Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 2005; 23: 8978-91.
42. Gogas H, Ioannovich J, Dafni U, et al., Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-18.